We use cookies to personalize our website and to analyze web traffic to improve the user experience. You may decline these cookies although certain areas of the site may not function without them. Please refer to our privacy policy for more information.

Settings

Save and close

JAX Frontend Platform

Give

Patient-Derived Acute Myeloid Leukemia (AML) Models

A unique platform that accurately recapitulates leukemia phenotypes in vivo, the AML Patient-Derived Xenograft (PDX) models are designed to promote the optimal leukemia conditions.

REQUEST A QUOTE

[email protected] | 1.800.422.6423 (US) | 1.207.288.5845 (International)

To better analyze the effectiveness of potential new drugs- alone or in combination- to treat Acute myeloid leukemia (AML), JAX offers AML Patient-Derived Xenograft (PDX) models with varying mutational profiles and treatment histories. These PDX models (Townsend et al.) have been engrafted in the highly immunodeficient NSG™-SGM3 (stock #013062), the mouse strain that most effectively engrafts human myeloid leukemia.

NSG™-SGM3 Mice: Engineered for Improved AML modeling

  • Robust engraftment of the primary AML samples in NSG™-SGM3 mice has been confirmed. This multi-allelic strain combines an immunodeficient environment with the expression of three transgenic human cytokines (SCF, GM-CSF, & IL-3) supportive of human myeloid cell expansion.
  • Client-sponsored efficacy studies can be executed by the JAX® In Vivo Pharmacology Service group.
  • Engrafted mice can be delivered to the client site.

Data. Faster.

PDX Live: Off-the-Shelf Low Passage Tumor Models

Learn More
Leading the search for tomorrow's cures

©2025 The Jackson Laboratory